Neuralstem Collaborator to Present Stroke Study Results at Stem Cell & Regenerative Medicine Conference
ROCKVILLE, Md., Sept. 7 /PRNewswire-FirstCall/ -- Neuralstem,
Inc. (NYSE Amex: CUR) announced that Dr. Shinn-Zong Lin,
Superintendent at China Medical University Hospital, will present
results from a study entitled, "Intracerebral Implantation of
Adherent Human Neural Stem Cells (or Neurals Progenitor Cells or
"NPCs") to Reverse Motor Deficits in Chronic Stroke Rats," at the
Stem Cells USA & Regenerative Medical Conference in
Philadelphia, PA, on September 14, 2010.
(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )
"We are encouraged by Dr. Lin's findings with our stem cells,
which represent a significant milestone for Neuralstem," said
Richard Garr, Neuralstem CEO and President. "Unlike our programs in
ALS and chronic spinal cord injury, in which our cells are
transplanted into the spinal cord, we will treat stroke-related
movement disorders by direct transplantation into the brain. We are
developing stroke clinical programs both in the U.S. and in Taiwan,
and hope to start our first trial in 2011."
The company also announced that CEO and President, Richard Garr,
will take part in a panel at the conference with other industry
leaders entitled, "IP Issues and Licensing Arrangements," on
September 14, 2010. The panel will discuss intellectual property
patent law and licensing issues, as well as how to manage both IP
issues and biotech licensing agreements.
About Neuralstem
Neuralstem's patented technology enables the ability to produce
neural stem cells of the human brain and spinal cord in commercial
quantities, and the ability to control the differentiation of these
cells constitutively into mature, physiologically relevant human
neurons and glia. Neuralstem is in a Phase I safety clinical trial
for Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou
Gehrig's disease. The company is also targeting major central
nervous system diseases in addition to ALS, including traumatic
spinal cord injury, ischemic spastic paraplegia, and Huntington's
disease. The company has also submitted an IND application to the
FDA for a Phase I safety trial in chronic spinal cord injury.
Through its proprietary screening technology, Neuralstem has
discovered and patented compounds that may stimulate the brain's
capacity to generate new neurons, possibly reversing the
pathologies of some central nervous system conditions. The company
plans to initiate clinical trials to treat Alzheimer's disease and
major depression with its lead compound, as well as pursue
additional indications, including traumatic brain injury,
posttraumatic stress syndrome, stroke and schizophrenia.
For more information, please go to www.neuralstem.com Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that such
forward-looking statements in this press release regarding
potential applications of Neuralstem's technologies constitute
forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development
and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need
for future capital, dependence upon collaborators and maintenance
of our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Neuralstem's periodic reports, including the
annual report on Form 10-K for the year ended December 31, 2009,
and in its quarterly report on Form 10-Q for the period ended June
30, 2010.
Photo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO
Source: Neuralstem, Inc.
CONTACT: Meg McElroy, Shareholder Relations, +1-301-366-4960, or
Deanne
Eagle, Media Relations, +1-917-837-5866, or Susan Roush, Investor
Relations,
+1-818-222-8330, all of Neuralstem, Inc.
Web Site: http://www.neuralstem.com/
Posted: September 2010
